FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry, particularly to haemostasis-enhancing variants of factor Xa, nucleic acids coding them, producing and using factor Xa for treating haemostasis-related disorders. The declared factor Xa contains an amino acid sequence in a sequence of wild-type factor X in position 16, 17 or 194 in a chymotrypsin numbering system.
EFFECT: invention enables the haemostasis enhancement effectively.
21 cl, 11 dwg, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED FACTOR VII-BASED POLYPEPTIDES AND THEREOF APPLICATION | 2008 |
|
RU2571931C2 |
| MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE | 2007 |
|
RU2466141C2 |
| COMPOSITIONS COMPRISING HETEROGENEOUS POPULATIONS OF RECOMBINANT HUMAN CLOTTING FACTOR Xa PROTEINS | 2014 |
|
RU2648144C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| MODIFIED VON WILLEBRAND FACTOR WITH PROLONGED HALF-CYCLE IN VIVO, USING IT AND METHODS FOR PREPARING | 2009 |
|
RU2528855C2 |
| MODIFIED VITAMIN K DEPENDENT POLYPEPTIDES | 2005 |
|
RU2396347C2 |
| HOST CELL CONTAINING VECTOR FOR PRODUCING PROTEINS REQUIRING GAMMA-CARBOXYLATION | 2006 |
|
RU2415934C2 |
| METHOD FOR EVALUATING REACTION OF BLOOD COAGULATION | 2013 |
|
RU2683933C2 |
| ANTIBODY WHICH IS CAPABLE OF NEUTRALIZING A SUBSTANCE HAVING AN ACTIVITY OF AN ALTERNATIVE COAGULATION FACTOR FUNCTION VIII (FVIII) | 2015 |
|
RU2737145C2 |
| NEW THROMBOMODULINE FUSION PROTEINS PROVIDING DIRECTIONAL TRANSFER TO TISSUE FACTOR AS ANTICOAGULANTS | 2003 |
|
RU2320366C2 |
